Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Medtronic
Merck
Colorcon
Boehringer Ingelheim

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANNABIDIOL

➤ Subscribe for complete access

« Back to Dashboard

505(b)(2) Clinical Trials for CANNABIDIOL

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT04423341 ↗ Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Completed Benign Essential Blepharospasm Research Foundation Phase 2/Phase 3 2020-05-20 The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.
OTC NCT04423341 ↗ Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Completed GW Pharmaceuticals Ltd. Phase 2/Phase 3 2020-05-20 The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.
OTC NCT04423341 ↗ Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Completed Smith-Kettlewell Eye Research Institute Phase 2/Phase 3 2020-05-20 The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.
OTC NCT04423341 ↗ Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Completed Silkiss Eye Surgery Phase 2/Phase 3 2020-05-20 The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for CANNABIDIOL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00241592 ↗ Vaporization as a Smokeless Cannabis Delivery System Completed University of California, San Francisco Phase 1 2004-08-01 A study to evaluate the use of a vaporization system as a smokeless delivery system for inhaled marijuana.
NCT00241592 ↗ Vaporization as a Smokeless Cannabis Delivery System Completed Center for Medicinal Cannabis Research Phase 1 2004-08-01 A study to evaluate the use of a vaporization system as a smokeless delivery system for inhaled marijuana.
NCT00309413 ↗ A Clinical Trial on the Antipsychotic Properties of Cannabidiol Completed Coordinating Centre for Clinical Trials Cologne Phase 2 2006-03-01 The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.
NCT00309413 ↗ A Clinical Trial on the Antipsychotic Properties of Cannabidiol Completed Stanley Medical Research Institute Phase 2 2006-03-01 The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CANNABIDIOL

Condition Name

Condition Name for CANNABIDIOL
Intervention Trials
Epilepsy 18
Cannabis 17
CBD 13
Schizophrenia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CANNABIDIOL
Intervention Trials
Marijuana Abuse 39
Syndrome 26
Epilepsy 18
Disease 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CANNABIDIOL

Trials by Country

Trials by Country for CANNABIDIOL
Location Trials
United States 389
Canada 26
United Kingdom 23
Germany 19
Israel 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CANNABIDIOL
Location Trials
New York 34
California 32
Florida 23
Pennsylvania 20
Maryland 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CANNABIDIOL

Clinical Trial Phase

Clinical Trial Phase for CANNABIDIOL
Clinical Trial Phase Trials
Phase 4 11
Phase 3 35
Phase 2/Phase 3 19
[disabled in preview] 92
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CANNABIDIOL
Clinical Trial Phase Trials
Completed 79
Recruiting 78
Not yet recruiting 50
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CANNABIDIOL

Sponsor Name

Sponsor Name for CANNABIDIOL
Sponsor Trials
GW Research Ltd 25
GW Pharmaceuticals Ltd. 15
National Institute on Drug Abuse (NIDA) 13
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CANNABIDIOL
Sponsor Trials
Other 316
Industry 102
NIH 20
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Dow
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.